Madelaine Feldman, MD, FACR
Chair, Alliance for Safe Biologic Medicine
Dr. Madelaine Feldman is a practicing rheumatologist with over 20 years of experience and began her term as chair of the Alliance for Safe Biologic Medicines in 2017.
She has been recognized as one of New Orleans’ “Top Doctors” for over 10 years and received her training from Tulane University School of Medicine, where she also completed her internal medicine residency and rheumatology fellowship. Dr. Feldman continues her devotion to Tulane University School of Medicine serving as a Clinical Associate Professor of Medicine.
Dr. Feldman is also a founding member and past president of the Rheumatology Alliance of Louisiana, vice-president of the Coalition of State Rheumatology Organizations, board liaison to the Association of Women in Rheumatology and recently served on the insurance subcommittee for the American College of Rheumatology.
Michael Reilly, ESQ
Executive Director, Alliance for Safe Biologic Medicines
Michael Reilly has served as the executive director of ASBM since its inception in 2010. He has more than a decade of experience in the federal government developing and implementing healthcare policy.
Mr. Reilly served as the associate deputy secretary at the U.S. Department of Health and Human Services (HHS) from 2005-2008 responsible for policy development and implementation, as well as regulatory oversight for issues involving CMS and the FDA. In addition to serving as the associate deputy secretary, Mr. Reilly served as a senior advisor to the assistant secretary for public affairs and the assistant secretary for planning and evaluation at HHS from 2002-2005.
Mr. Reilly has been quoted in a series of FDA publications and co-authored many articles on biosimilars for the Generics and Biosimilars Initiative Journal. He has also presented to health regulators worldwide, including the Australian TGA, Health Canada and the World Health Organization (WHO).
Philip J. Schneider, MS, FASHP
Advisory Board Chair, Alliance for Safe Biologic Medicines
Philip Schneider has served as ASBM’s Advisory Board chair since 2014. He is currently Professor and Associate Dean for Academic and Professional Affairs for the University of Arizona College of Pharmacy, where he provides oversight of educational initiatives at the newly created Phoenix Biomedical Campus.
Prior to this position, he held positions at The Ohio State University for 33 years. This included work directing the Pharmacy Residency program at OSU where he also led an interprofessional program to improve the medication use system to reduce adverse drug events.
Dr. Schneider is a past president of the American Society of Health-System Pharmacists (ASHP) and has served as chairman of the Board of Pharmaceutical Practice of the International Pharmaceutical Federation (FIP). He was the 2008 recipient of the Harvey A.K Whitney award, known as health-system pharmacy’s highest honor, for his outstanding contributions.
Harry L. Gewanter, MD, FAAP, FACR, MACR
Immediate Past Chair, Alliance for Safe Biologics
Dr. Gewanter is a pediatric rheumatologist and chair of ASBM from 2014-2017. Prior to being named chair, Dr. Gewanter served on ASBM’s International Advisory Board. While chair, he provided valuable testimony to health regulators worldwide, including the World Health Organization. ASBM expanded globally in its advocacy efforts and with its membership under his chairmanship.
Dr. Gewanter is a graduate of Duke University and received his medical training at Wayne State University. He conducted his pediatric internship and residency at the University of Rochester/Strong Memorial Hospital. He has practiced in Richmond Virginia since 1983.
After more than three decades, Dr. Gewanter decided to retire from clinical practice to focus his efforts advocating for systemic change for people with disabilities. He is especially passionate on issues affecting children and youth with special health care needs.
Richard Dolinar, MD
Past Chair, Alliance for Safe Biologic Medicines
A clinical endocrinologist, Dr. Dolinar was ASBM’s first chair and served from 2010-2013. Under his leadership, ASBM grew into an authority known for its unbiased research and information on biosimilars policy issues. He frequently testified before the U.S. Congress, Food and Drug Administration (FDA), and state legislatures around the United States. Dr. Dolinar was also the first chair to testify before the World Health Organization.
Dr. Dolinar received his medical degree from The State University of New York and did his Fellowship at Duke University. He is a past board member of the American Association of Clinical Endocrinologists (AACE) and serves on its National Legislative and Regulatory Committee.
Dr. Dolinar resides in Arizona where he continues to practice at the Arizona Endocrinology Center in Phoenix.